Developing a virtual twin for personalized cancer treatment with CAR-T cell therapy

NewsGuard 100/100 Score

In recent years, cancer immunotherapies have established themselves as a further pillar of medical oncology alongside traditional treatment options (surgery, radiotherapy and chemotherapy). The advantages of personalized treatment approaches, such as CAR-T cell therapy, also include more precise phenotyping of individual patients.

Numerous clinical, imaging, molecular and cell analytical data are collected and processed for each patient for diagnosis, treatment decisions and follow-up. The totality of all patient data within a clinical picture harbors enormous potential for improving diagnosis and therapy for future patients. One approach to realizing this potential is the concept of the virtual twin. This involves merging certain molecular and cellular characteristics of a person and their clinical progression data into a digital representation, which is regularly updated using a series of data variables. Based on comparative data from patients with similar characteristics, the virtual twin can then be used to simulate prognoses regarding the course of the disease or various treatment options.

Corresponding concepts for virtual twins and the first promising models already exist in the field of cardiovascular diseases. In the EU project CERTAINTY, modules are now to be developed for a corresponding virtual twin for the treatment of cancer patients with CAR-T cell therapies. This will support doctors in selecting the best possible therapy in the future and also relieve the burden on the healthcare system through the more efficient use of cost-intensive drugs.

The virtual twin will initially be developed as an example for multiple myeloma (MM), a malignant disease of the bone marrow. The plan is for it to comprehensively reflect the individual pathophysiology of patients who are eligible for or undergoing cellular immunotherapies and to be updated regularly. A particular focus is on the integration of molecular patterns into the digital representation. Other key technologies include the collection and processing of large amounts of data (big data processing), machine learning, personalized in vitro models and software-supported mechanistic models. Another focus of work is the development of interfaces that ensure data access and interaction between different physical and digital systems, always taking data protection into account.

Other aspects taken into account in the project are the integration of socio-economic factors that can influence the course of the disease, as well as future applications for patients.

The EU consortium "CERTAINTY - A cellular immunotherapy virtual twin for personalized cancer treatment" is being funded by the European Union with almost EUR 10 million over the next 4.5 years.

UKW will host the virtual twin concept for CAR-T cell therapy in multiple myeloma

The University Hospital of Würzburg (UKW) is a European leader in the development and clinical use of innovative immunotherapies with CAR-T cells and T-cell engaging antibodies to treat multiple myeloma. In CERTAINTY, UKW will contribute its expertise in pre-clinical, translational and clinical research with CAR-T cell therapy in multiple myeloma. Further, UKW will contribute its experience in the development of Artificial Intelligence-supported CAR-T cell manufacturing and treatment models.
A key objective for UKW is to implement the virtual twin concept in CAR-T cell therapy campaigns in the pre-clinical and eventually, the clinical setting. The UKW team will be led by Senior Scientist and Project Lead Dr. Miriam Alb at the Chair in Cellular Immunotherapy (Professor Michael Hudecek) at the Department of Medicine II (Chair: Professor Hermann Einsele). The UKW team is leading several National and European Research Projects (e.g. the EU IMI Project T2EVOLVE) and will provide a dense network and create synergies with key stakeholders in the field of CAR-T cell therapy and multiple myeloma.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts